6 completed. 6 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 6 |
| Phase 2 | 2 | Completed 2 |
Follow Pulmonary Emphysema: new trials by email Literature Review of Pulmonary Emphysema trials Research Report on Pulmonary Emphysema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD) Alpha-1 MP, 0.9% Sodium Chloride for Injection, USP - Pulmonary Emphysema in Alpha-1 PI Deficiency | Phase 3 | Completed | Grifols Therapeutics LLC | 345 | 2014-04-01 | 2026-10-01 |
| The Effect and Mechanism of Bronchoscopic Lung Volume Reduction by Endobronchial Valve in Korean Emphysema Patients Endobronchial valve - Pulmonary Emphysema | Phase 3 | Completed | Asan Medical Center | 43 | 2013-03-01 | 2017-06-27 |
| AeriSeal® System for Lung Volume Reduction in Patients With Advanced Emphysema AeriSeal System - Pulmonary Emphysema, COPD | Phase 2 / Phase 3 | Completed | Aeris Therapeutics | 20 | 2010-08-01 | 2011-10-21 |
| Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency Kamada-API - Alpha 1-Antitrypsin Deficiency | Phase 2 / Phase 3 | Completed | Kamada, Ltd. | 50 | 2007-03-01 | 2007-10-17 |
| The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency alpha-1 proteinase inhibitor (human) - Alpha 1-Antitrypsin Deficiency | Phase 3 | Completed | Grifols Therapeutics LLC | 38 | 2006-06-01 | 2014-08-19 |
| Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults Alpha-1 MP, alpha-1 proteinase inhibitor (human) - Alpha 1-Antitrypsin Deficiency | Phase 3 | Completed | Grifols Therapeutics LLC | 24 | 2006-05-01 | 2014-09-09 |
alpha 1-Antitrypsin Deficiency (4) · Emphysema (2) · Pulmonary Disease, Chronic Obstructive (2) · Lung Diseases (1) · Pathologic Processes (1) · Respiratory Aspiration (1) · Respiratory Tract Diseases (1)
Chronic Disease (6) · Disease Attributes (6) · Lung Diseases, Obstructive (6) · Pathological Conditions, Signs and Symptoms (6) · Lung Diseases (5) · Pathologic Processes (5) · Respiratory Tract Diseases (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Digestive System Diseases (4) · Emphysema (4) · Genetic Diseases, Inborn (4) · Liver Diseases (4) · Pulmonary Disease, Chronic Obstructive (4) · Subcutaneous Emphysema (4) · Respiration Disorders (1)
Mp alpha1 receptor (2) · alpha 1-Antitrypsin (2) · Injections (1) · Sodium Chloride (1)
Grifols Therapeutics LLC (3) · Aeris Therapeutics (1) · Asan Medical Center (1) · Kamada, Ltd. (1)
United States (4) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · Denmark (1) · Estonia (1) · Finland (1) · France (1) · Germany (1) · Israel (1) · Moldova (1) · New Zealand (1) · Poland (1) · Romania (1)
Kim Hanna, MSc (2) · Robert A Sandhaus, M.D. (1) · Sei Won Lee, MD (1)
PMID 20920295, PMID 22374920, PMID 23822603, PMID 25727857, PMID 26251590